IL-13 Ralpha2-mediated interleukin-13 neutralization represses in vivo progressive growth of a T-cell lymphoma.
Dalton's lymphoma (DL) is a T-cell lymphoma of spontaneous origin, characterized by highly invasive and malignant nature, killing the host in a very short period of life span. DL-bearing host is reflected by very high titer of IL-13 in serum. Therefore, we hypothesized that over expression of IL-13 may greatly affect the growth of DL-cells in a tumor-bearing host. In this study, to assess the involvement of IL-13 in DL-cell progression, we have blocked the IL-13 activity/signalling by the systemic delivery of non-signaling decoy receptor IL-13 Ralpha2, and IL-13 level vs DL-cell proliferation were measured. We observed that systemic delivery of IL-13 Ralpha2 inhibits the DL-cell progression in much extent and enhances the survival and longevity of DL-bearing mice. Further, this study re-inforce the therapeutic advantage of IL-13 Ralpha2 in a T-cell lymphoma tumor system.
Deepak
P
P
Centre of Advance Study in Zoology, Banaras Hindu University, Varanasi, India.
Sanjay
K
K
Acharya
A
A
D000818:Animals; D049109:Cell Proliferation; D005260:Female; D018793:Interleukin-13 / Q000037:antagonists & inhibitors* / Q000097:blood / Q000378:metabolism; D053663:Interleukin-13 Receptor alpha2 Subunit / Q000008:administration & dosage / Q000627:therapeutic use*; D016399:Lymphoma, T-Cell / Q000188:drug therapy* / Q000378:metabolism; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D015398:Signal Transduction; D013997:Time Factors
D018793:Interleukin-13; D053663:Interleukin-13 Receptor alpha2 Subunit